Related to Lilly Pays BI €300M in Reciprocal Deal to Commercialize Joint Diabetes Pipeline

• Drug Giants Establish Problem-Solving Initiative
  
• Qiagen, Lilly Take on Companion Diagnostics
  
• ChemAxon Boosts Boehringer Ingelheim toward Next-Gen Cheminformatics
  
• Lilly Plans to Add $180 Million Insulin Manufacturing Investment
  
• OBT Joins Boehringer Ingelheim in Cancer Drug Collaboration
  
• ADA, Lilly Partner on Grant-Giving Diabetes Research Program
  
• Boehringer Ingelheim Enters Deal with DeveloGen with an Initial Fee of $9.5M
  
• Vitae Earns $8M Milestone from Boehringer Ingelheim
  
• Transition Therapeutics and Lilly Expand Diabetes Partnership through Licensing of the Latter’s Preclinical Candidates
  
• Vitae Earns $14M from Boehringer Ingelheim with Start of Phase I Development
  
• BI Reports Positive Phase III Data for Type 2 Diabetes Drug
  
• MacroGenics and Lilly Ponder Future of Diabetes mAb after Phase III Flop
  
• Lilly Sets Up Shanghai Diabetes Center to Develop Therapies for Chinese Patients
  
• Amylin Obtains Temporary Restraining Order Against Eli Lilly
  
• Court Vacates Temporary Restraining Order Against Lilly in Case Filed by Amylin
  
• Setback, and Success, for BI-Lilly Diabetes Alliance
  
• FDA Approves Type 2 Diabetes Drug from Boehringer Ingelheim and Lilly
  
• Amylin Takes Lilly to Court over Diabetes Drug Development Deal with Boehringer Ingelheim
  
• BI and Lilly’s Linagliptin Now Approved to Treat Type 2 Diabetes in Europe
  
• Promising Data for Type 1 and 2 Diabetes Candidates Presented at ADA Meeting